Recombinant human granulocyte stimulating factor

Pharmacology: This product is human granulocyte colony-stimulating factor (rhG-CSF) produced by genetic recombination technology. Compared with natural products, the biological activity is basically the same in vivo and in vitro. rhG-CSF is one of the main cytokines that regulate granulocyte hematopoiesis in the bone marrow. It selectively acts on granulocyte hematopoietic progenitor cells, promotes their proliferation and differentiation, and can increase the function of terminally differentiated granulocyte cells. Toxicology: Acute toxicity: A single injection of 5040 μg/kg of this product into the tail vein of mice is equivalent to 1000 times the general clinical injection dose. No poisoning reactions were observed after 10 consecutive days of observation. Subacute toxicity: The no-effect dose for mice after 4 weeks of administration (intravenous and subcutaneous injection) and 13 weeks (intravenous injection) was 1 μg/kg/day. Giving 1

Main ingredients: recombinant human granulocyte colony stimulating factor

This product is a colorless transparent liquid.

1. Promote the increase of neutrophil count after bone marrow transplantation. 2. Neutropenia caused by cancer chemotherapy, including malignant lymphoma, small cell lung cancer, embryonal cell tumor (testicular tumor, ovarian tumor, etc.), neuroblastoma, etc. 3. Neutropenia associated with myelodysplastic syndrome. 4. Neutropenia associated with aplastic anemia. 5. Congenital idiopathic neutropenia.

1. For tumors, it is used for neutropenia caused by chemotherapy, etc. For adult patients whose neutrophil count drops below 1000/mm3 (white blood cell count 2000/mm3) after chemotherapy, 2-5μg/kg should be administered subcutaneously or intravenously once a day after starting chemotherapy. For children whose neutrophil count drops below 500/mm3 (white blood cell count 1000/mm3) after chemotherapy, 2-5μg/kg should be administered subcutaneously or intravenously once a day after starting chemotherapy. When the neutrophil count rises back to above 5000/mm3 (white blood cell count 10000/mm3), stop administering the drug. 2. Neutropenia caused by chemotherapy for acute leukemia Leukemia patients after chemotherapy

1 Musculoskeletal system: sometimes there will be muscle soreness, bone pain, back pain, chest pain. 2 Digestive system: sometimes there will be loss of appetite, or liver alanine aminotransferase and aspartate aminotransferase will increase. 3 Others: some people will have fever, headache, fatigue and rash, ALP and LDH will increase. 4 Very few people will experience shock, interstitial pneumonia, adult respiratory distress syndrome, and increase in immature cells.

1. Patients who are allergic to granulocyte colony stimulating factor and other preparations expressed by Escherichia coli are contraindicated. 2. Patients with severe liver, kidney, heart, and lung dysfunction are contraindicated. 3. Myeloid leukemia patients whose immature granulocytes in the bone marrow have not been significantly reduced or myeloid leukemia patients with immature granulocytes detected in peripheral blood.

It is not completely clear. Drugs that promote the release of white blood cells (such as lithium) should be used with caution.

Store at 2～8℃ away from light +2 years

Original solution